Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Germany flag Germany · Delayed Price · Currency is EUR
4.400
-0.080 (-1.79%)
Last updated: Dec 4, 2025, 9:59 AM CET
92.98%
Market Cap 28.04B
Revenue (ttm) 1.57B
Net Income (ttm) 568.30M
Shares Out n/a
EPS (ttm) 0.10
PE Ratio 49.33
Forward PE 44.24
Dividend 0.04 (0.91%)
Ex-Dividend Date Sep 22, 2025
Volume n/a
Average Volume 553
Open 4.380
Previous Close 4.480
Day's Range 4.380 - 4.400
52-Week Range 1.970 - 4.480
Beta n/a
RSI 59.00
Earnings Date Nov 17, 2025

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 8,989
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3KY
Full Company Profile

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.